Catalent, Inc. (NYSE:CTLT) Receives $63.40 Average PT from Analysts

Shares of Catalent, Inc. (NYSE:CTLT) have been given an average recommendation of “Hold” by the seven brokerages that are presently covering the firm, MarketBeat Ratings reports. Seven equities research analysts have rated the stock with a hold rating. The average 12-month price objective among brokers that have issued a report on the stock in the last year is $63.40.

Separately, StockNews.com initiated coverage on Catalent in a report on Tuesday. They set a “hold” rating for the company.

Catalent Price Performance

Shares of CTLT opened at $63.48 on Tuesday. The company has a debt-to-equity ratio of 1.38, a quick ratio of 1.96 and a current ratio of 2.51. Catalent has a fifty-two week low of $41.15 and a fifty-two week high of $63.50. The firm has a 50-day simple moving average of $62.69 and a 200-day simple moving average of $60.68. The company has a market capitalization of $11.52 billion, a price-to-earnings ratio of -28.09, a price-to-earnings-growth ratio of 2.69 and a beta of 1.15.

Catalent (NYSE:CTLT) last posted its quarterly earnings data on Tuesday, November 5th. The company reported ($0.13) EPS for the quarter, missing the consensus estimate of $0.05 by ($0.18). Catalent had a negative net margin of 9.28% and a negative return on equity of 0.66%. The company had revenue of $1.02 billion for the quarter, compared to analysts’ expectations of $1.06 billion. During the same period in the prior year, the company earned ($0.10) earnings per share. The firm’s revenue was up 4.2% on a year-over-year basis. On average, equities research analysts anticipate that Catalent will post 0.78 earnings per share for the current year.

Insider Activity at Catalent

In related news, Director Michelle R. Ryan sold 2,800 shares of the firm’s stock in a transaction dated Monday, November 11th. The shares were sold at an average price of $59.70, for a total value of $167,160.00. Following the completion of the sale, the director now owns 10,835 shares in the company, valued at $646,849.50. This trade represents a 20.54 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Company insiders own 0.31% of the company’s stock.

Institutional Inflows and Outflows

A number of hedge funds have recently added to or reduced their stakes in the stock. Brooklyn Investment Group acquired a new stake in shares of Catalent in the 3rd quarter worth approximately $31,000. Blue Trust Inc. grew its holdings in Catalent by 88.7% in the fourth quarter. Blue Trust Inc. now owns 615 shares of the company’s stock valued at $37,000 after purchasing an additional 289 shares during the last quarter. Sentry Investment Management LLC purchased a new position in shares of Catalent in the third quarter valued at $53,000. Thurston Springer Miller Herd & Titak Inc. raised its stake in shares of Catalent by 57.5% during the 3rd quarter. Thurston Springer Miller Herd & Titak Inc. now owns 1,181 shares of the company’s stock worth $72,000 after buying an additional 431 shares during the last quarter. Finally, Intact Investment Management Inc. purchased a new stake in shares of Catalent in the 3rd quarter worth about $73,000.

Catalent Company Profile

Catalent, Inc, together with its subsidiaries, develops and manufactures solutions for drugs, protein-based biologics, cell and gene therapies, and consumer health products worldwide. It operates in two segments, Biologics, and Pharma and Consumer Health. The Biologics segment provides formulation, development, and manufacturing for biologic proteins, cell gene, and other nucleic acid therapies; pDNA, iPSCs, oncolytic viruses, and vaccines; formulation, development, and manufacturing for parenteral dose forms, including vials, prefilled syringes, and cartridges; and analytical development and testing services for large molecules.